Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Qingdao NovelBeam Technology Co., Ltd. specializes in advanced medical instruments and supplies, focusing on innovative diagnostic and therapeutic solutions primarily for the Chinese healthcare market. The company benefits from a strong gross margin of 100% and a low debt-to-equity ratio of 0.07, positioning it well for growth in a rapidly expanding sector.
NovelBeam generates revenue through the sale of high-margin medical devices and consumables, leveraging its proprietary technology to maintain pricing power. The company's competitive advantage lies in its strong R&D capabilities and established relationships with hospitals across China, allowing for rapid adoption of new products.
Regulatory approvals for new medical devices
Market penetration in Tier 1 and Tier 2 cities in China
Partnerships with major hospital networks
Advancements in proprietary technology
Regulatory changes impacting product approvals
Technological disruption from new entrants
Increased competition from domestic and international medical device manufacturers
Potential price erosion due to competitive pressures
Low liquidity risk due to high current ratio of 5.17
Minimal debt exposure
moderate - The demand for medical instruments is somewhat insulated from economic cycles, but overall healthcare spending can be affected by GDP growth.
Minimal - Low debt levels reduce sensitivity to interest rate changes, but higher rates could impact consumer spending on healthcare services.
minimal
growth - The company's strong revenue growth and innovative product pipeline attract growth-focused investors.
high - The stock has shown significant volatility with a 3-month return of 213.8%.
